SOUTH SAN FRANCISCO, Calif., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing next-generation targeted therapies for patients with immune-mediated diseases, today announced the closing of its upsized underwritten public offering of 20,297,500 shares of its common stock, including the full exercise of the underwriters' option to purchase an additional 2,647,500 shares, at a price to the public of $17.00 per share. The gross proceeds to Alumis ...

Core Insights - Alumis Inc. is a late-stage biopharma company focused on developing next-generation targeted therapies for immune-mediated diseases [2] - The company is leveraging a proprietary data analytics platform to create a pipeline of oral tyrosine kinase 2 inhibitors and other therapies [2] Company Overview - Alumis is developing envudeucitinib (formerly ESK-001) for systemic immune-mediated disorders, including moderate-to-severe plaque psoriasis and systemic lupus erythematosus [2] - The pipeline also includes A-005 for neuroinflammatory and neurodegenerative diseases, and lonigutamab for thyroid eye disease [2] - Several preclinical programs are being identified through a precision approach [2] Upcoming Events - Alumis will participate in the Guggenheim's 2nd Annual Healthcare Innovation Conference from November 10-12, 2025, with a fireside chat scheduled for November 11, 2025, at 1:30 pm ET [4] - The company will also present at the Stifel 2025 Healthcare Conference from November 11-13, 2025, on November 12, 2025, at 2:00 pm ET [4]

Core Insights - Alumis Inc. is a late-stage biopharma company focused on developing next-generation targeted therapies for immune-mediated diseases [2] - The company is leveraging a proprietary data analytics platform to create a pipeline of oral tyrosine kinase 2 inhibitors and other therapies [2] - Upcoming investor conferences will feature Alumis, providing opportunities for engagement with investors [1][4] Company Overview - Alumis is developing therapies aimed at improving health outcomes for patients with immune-mediated diseases, including moderate-to-severe plaque psoriasis and systemic lupus erythematosus [2] - The pipeline includes envudeucitinib (formerly ESK-001) and A-005 for various systemic and neuroinflammatory conditions, as well as lonigutamab for thyroid eye disease [2] - The company has several preclinical programs identified through its precision approach [2] Upcoming Events - Alumis will participate in multiple investor conferences in September 2025, including: - Cantor Global Healthcare Conference on September 3 at 9:45 am ET [4] - Wells Fargo 2025 Healthcare Conference on September 5 at 9:30 am ET [4] - Morgan Stanley 23rd Annual Global Healthcare Conference on September 8 at 4:50 pm ET [4] - H.C. Wainwright 27th Annual Global Investment Conference on September 9 at 10:30 am ET [4] - Baird 2025 Global Healthcare Conference on September 10 at 2:35 pm ET [4] - Stifel 2025 Virtual Immunology & Inflammation Forum on September 16 at 12:30 pm ET [4]

Core Insights - Alumis Inc. has completed patient enrollment in its global LUMUS Phase 2b trial for ESK-001, a next-generation oral TYK2 inhibitor targeting systemic lupus erythematosus (SLE), with topline data expected in Q3 2026 [1][5]. Company Overview - Alumis is a late-stage biopharma company focused on developing targeted therapies for immune-mediated diseases, leveraging a proprietary data analytics platform [7]. - The company is developing a pipeline of oral TYK2 inhibitors, including ESK-001 for SLE and moderate-to-severe plaque psoriasis, and A-005 for neuroinflammatory and neurodegenerative diseases [7]. Clinical Trial Details - The LUMUS Phase 2b trial is a randomized, double-blind, placebo-controlled study involving 408 patients with moderately-to-severely active, autoantibody-positive SLE, assessing the efficacy of ESK-001 over 48 weeks [2][5]. - The primary endpoint of the trial is to evaluate improvements in overall disease activity using the British Isles Lupus Assessment Group-based Composite Lupus Assessment (BICLA) at Week 48 [2][5]. Drug Mechanism and Efficacy - ESK-001 is designed to selectively target key inflammatory drivers, such as type 1 interferon (IFN), aiming for maximal inhibition while minimizing off-target effects [3][4]. - Clinical data from the psoriasis program indicates that ESK-001 downregulates key cytokines and disease biomarkers, suggesting potential to reduce SLE disease activity [4]. Future Prospects - The company anticipates that ESK-001 could provide biologic-like clinical responses for SLE, based on its performance in previous clinical studies [4].

Company Overview - Alumis Inc. is a late-stage biopharma company focused on developing next-generation targeted therapies for immune-mediated diseases [3] - The company utilizes a proprietary data analytics platform and precision approach to enhance patient health and outcomes [3] Pipeline Development - Alumis is developing a pipeline of oral tyrosine kinase 2 inhibitors, including ESK-001 for systemic immune-mediated disorders like moderate-to-severe plaque psoriasis and systemic lupus erythematosus [3] - A-005 is being developed for neuroinflammatory and neurodegenerative diseases [3] - The pipeline also features lonigutamab, an anti-insulin-like growth factor 1 receptor therapy for thyroid eye disease, along with several preclinical programs [3] Upcoming Events - Martin Babler, President and CEO of Alumis, will present at the Jefferies Global Healthcare Conference on June 4, 2025, at 3:10 p.m. ET [1] - A live webcast of the presentation will be available on the Alumis website, with a replay archived for 90 days [2]

Company Overview - Alumis Inc. has completed its merger with ACELYRIN, Inc., establishing itself as a leading clinical-stage biopharma company with a differentiated portfolio of therapies and a strong balance sheet [1][3] - Each ACELYRIN stockholder will receive 0.4814 shares of Alumis common stock for each share of ACELYRIN common stock owned, with ACELYRIN common stock ceasing to trade on NASDAQ [2] Financial Position - The merger significantly strengthens Alumis' balance sheet, allowing for the advancement of its late-stage portfolio and the development of transformative therapies for patients [3] - Alumis now has a cash runway that extends into 2027, supporting multiple planned key data readouts [3] Product Pipeline - Alumis is developing next-generation targeted therapies for immune-mediated diseases, including oral tyrosine kinase 2 inhibitors such as ESK-001 for systemic immune-mediated disorders and A-005 for neuroinflammatory diseases [5] - The pipeline also includes lonigutamab, an anti–insulin-like growth factor 1 receptor therapy for thyroid eye disease, along with several preclinical programs identified through a precision approach [5] Advisory Team - Morgan Stanley & Co. LLC served as the financial advisor to Alumis, while Cooley LLP acted as its legal counsel [4] - Guggenheim Securities, LLC served as the financial advisor to ACELYRIN, with Fenwick & West LLP and Paul Hastings LLP providing legal counsel [4]